“The potential is clearly vast...” Joe, I think that’s what Steve King was conveying to shareholders when he used the term, “Astronomical”, SK is not generally known for employing hype, as many here will attest to be the case. That is not a signal that should be ignored. The extensive list of cancers that I occasionally re-publish, is meant to help remind investors just how broad the potential market for Bavi actually could be.
While SUNRISE matures, and look-ins occur, Peregrine will be running parallel clinical trials to bolster the SUNRISE data for FDA and certain other interested parties.
Phase II/III breast cancer,
Phase II NSCLC trial in combination with AstraZeneca's anti-PD-L1 antibody, durvalumab,
Phase I trial in multiple cancer types also with durvalumab.
Peregrine has recently announced a custom-designed immuno-profiling clinical test that provides direct evidence of Bavituximab's immune modulation in the tumor microenvironment that can be used to evaluate the above mentioned trials while they are running.
Certainly this assay will be, or already has been, applied to the data that have been gleaned from patients in the phase I advanced melanoma trial of Bavi in combination with Yervoy, compared to Yervoy alone.
So, Peregrine will have a wide range of assay material that can show how the immune microenvironment progresses from a suppressed state to an immune active state when patients receive Bavituximab treatments in various combinations.
And certainly these data will be at the table for selected business development talks.
IMO
sunstar
News 
Market Data 
Discover 
AI
